VDAC1 and systemic lupus erythematosus: Using the VDAC1 oligomerisation inhibitor VBIT‐4, the authors were able to reduce lupus‐like symptoms in lupus‐prone mice, providing a rationale to target VDAC‐mediated mtDNA release in this disease 85.